From the Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach Tikva, Israel.
the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Pediatr Gastroenterol Nutr. 2022 Sep 1;75(3):244-251. doi: 10.1097/MPG.0000000000003521. Epub 2022 Aug 9.
Severe acute respiratory syndrome coronavirus 2, the novel coronavirus responsible for coronavirus disease (COVID-19), has been a major cause of morbidity and mortality worldwide. Gastrointestinal and hepatic manifestations during acute disease have been reported extensively in the literature. Post-COVID-19 cholangiopathy has been increasingly reported in adults. In children, data are sparse. Our aim was to describe pediatric patients who recovered from COVID-19 and later presented with liver injury.
This is a retrospective case series study of pediatric patients with post-COVID-19 liver manifestations. We collected data on demographics, medical history, clinical presentation, laboratory results, imaging, histology, treatment, and outcome.
We report 5 pediatric patients who recovered from COVID-19 and later presented with liver injury. Two types of clinical presentation were distinguishable. Two infants aged 3 and 5 months, previously healthy, presented with acute liver failure that rapidly progressed to liver transplantation. Their liver explant showed massive necrosis with cholangiolar proliferation and lymphocytic infiltrate. Three children, 2 aged 8 years and 1 aged 13 years, presented with hepatitis with cholestasis. Two children had a liver biopsy significant for lymphocytic portal and parenchyma inflammation, along with bile duct proliferations. All 3 were started on steroid treatment; liver enzymes improved, and they were weaned successfully from treatment. For all 5 patients, extensive etiology workup for infectious and metabolic etiologies was negative.
We report 2 distinct patterns of potentially long COVID-19 liver manifestations in children with common clinical, radiological, and histopathological characteristics after a thorough workup excluded other known etiologies.
导致冠状病毒病(COVID-19)的新型冠状病毒严重急性呼吸系统综合征冠状病毒 2 在全球范围内是发病率和死亡率的主要原因。文献中广泛报道了急性疾病期间的胃肠道和肝脏表现。越来越多的成年人报告了 COVID-19 后胆病。在儿童中,数据较少。我们的目的是描述从 COVID-19 中康复但后来出现肝损伤的儿科患者。
这是一项对 COVID-19 后肝脏表现的儿科患者的回顾性病例系列研究。我们收集了人口统计学、病史、临床表现、实验室结果、影像学、组织学、治疗和结果的数据。
我们报告了 5 例从 COVID-19 中康复但后来出现肝损伤的儿科患者。有两种不同的临床表现类型。2 名 3 个月和 5 个月大的婴儿,既往健康,表现为急性肝功能衰竭,迅速进展为肝移植。他们的肝活检显示大量坏死,伴有胆管增生和淋巴细胞浸润。另外 3 名儿童,2 名 8 岁和 1 名 13 岁,表现为肝炎伴胆汁淤积。2 名儿童的肝活检显示淋巴细胞门脉和实质炎症以及胆管增生。所有 3 名患者均开始接受类固醇治疗;肝酶改善,并成功地停止了治疗。对于所有 5 名患者,在进行了广泛的病因学检查排除了其他已知病因后,均未发现感染和代谢病因。
我们报告了 2 种不同模式的潜在长 COVID-19 肝脏表现,在进行了广泛的病因学检查排除了其他已知病因后,这些患儿具有共同的临床、放射学和组织病理学特征。